Liraglutide and Glycaemic Outcomes in the LEADER Trial

INTRODUCTION: The LEADER trial was a cardiovascular (CV) outcomes trial in patients with type 2 diabetes at high CV risk that compared liraglutide (n = 4668) with placebo (n = 4672) using a primary composite endpoint of 3-point major adverse CV events. The objective of this post hoc analysis was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zinman, Bernard, Nauck, Michael A., Bosch-Traberg, Heidrun, Frimer-Larsen, Helle, Ørsted, David D., Buse, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250637/
https://www.ncbi.nlm.nih.gov/pubmed/30392095
http://dx.doi.org/10.1007/s13300-018-0524-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250637/
https://www.ncbi.nlm.nih.gov/pubmed/30392095
http://dx.doi.org/10.1007/s13300-018-0524-z

Ejemplares similares